A Phase 2 interventional study of SHR-2173 injection and SHR-2173 injection in Generalized Myasthenia Gravis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.
Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 28th largest by planned enrollment of the 67 interventional ones that give a count, is one of 18 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 39 of the 59 other live ones, and was the 84th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in China, United States, France and 4 more countries
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
UCB Biopharma SRL · Sites in China, United States, Canada and 6 more countries
Ages 18+
Tongji Hospital · Sites in China
Ages 18–75
The Affiliated Hospital of Xuzhou Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 8 · Phase 3 26 · Phase 4 1
First in 2011; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 40 across the 67 interventional studies, 297 across the 21 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 88 have an industry lead sponsor. The 10 most frequent:
This study is registered under Guangdong Hengrui Pharmaceutical Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
23 of the studies in Myasthenia Gravis with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06447597Phase 3Shanghai Jiaolian Drug Research and Development Co., LtdA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. | 2026-12-30 |
| NCT07249632Phase 3RemeGen Co., Ltd.A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | 2026-12-31 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
Add all 23 to your calendar (.ics) → With an account.
Among the 88 studies in Myasthenia Gravis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of any of the following medical histories or comorbidities:
Use of any of the following drugs/treatments or participation in a clinical study:
Infection-related medical history and examinations:
General situation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-2173 injection
Drug: SHR-2173 injection
Drug: Placebo
SHR-2173 injection;High dose
SHR-2173 injection;Low dose
Placebo
Change from baseline in MG-ADL total score
Time frame: at Week 24
Change from baseline in Quantitative Myasthenia Gravis (QMG) score
Time frame: at Week 24
Change from baseline in Myasthenia Gravis Composite (MGC) total score
Time frame: at Week 24
Change from baseline in MG-ADL domain scores (ocular, bulbar, respiratory, limb)
Time frame: at Week 24
Change from baseline in QMG domain scores (ocular, bulbar, respiratory, limb)
Time frame: at Week 24
Proportion of participants with ≥3-point reduction from baseline in MG-ADL total score
Time frame: at Week 24
Proportion of participants with ≥50% reduction from baseline in MG-ADL total score
Time frame: at Week 24
Proportion of participants with ≥5-point reduction from baseline in QMG score
Time frame: at Week 24
Proportion of participants achieving Minimal Symptom Expression (MSE; MG-ADL total score 0 or 1) at Week 24
Time frame: at Week 24
Change from baseline in Myasthenia Gravis Quality of Life 15-item revised (MG-QoL15r) total score
Time frame: at Week 24
Change from baseline in Neuro-QoL Fatigue subscale score
Time frame: at Week 24
Change from baseline in European Quality of Life 5-Dimensions 5-Levels (EQ-5D-5L) index score
Time frame: at Week 24
Proportion of participants without rescue therapy
Time frame: through Week 24
Incidence, severity grading, and drug-relatedness of adverse events (AEs)
Time frame: through Week 24
Incidence, severity grading, and drug-relatedness of serious adverse events (SAEs)
Time frame: through Week 24
Incidence, severity grading, and drug-relatedness of adverse events of special interest (AESIs)
Time frame: through Week 24
Change from baseline in C-SSRS
Time frame: through Week 24
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's planned 13 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-2173
Guangdong Hengrui Pharmaceutical Co., Ltd →